Tesamorelin: What This Peptide Is and How It Works
Tesamorelin is a prescription peptide that stimulates the body to release its own growth hormone. It has one narrow FDA-approved use, yet it circulates in fitness discussions as a fat-loss and anti-aging agent. Our editorial team explains what tesamorelin is, how its mechanism differs from injecting growth hormone directly, what the clinical evidence shows, and why it is a serious medication rather than a casual supplement.
What tesamorelin is
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH), the natural signal the brain uses to tell the pituitary gland to release growth hormone. It is a peptide, meaning a short chain of amino acids, modified so it resists breakdown and lasts longer than natural GHRH.
It is administered by subcutaneous injection and is a prescription medication, not a dietary supplement. In the US it is marketed under the brand name Egrifta.
Tesamorelin belongs to a group sometimes called growth-hormone secretagogues, compounds that prompt the body to make more of its own growth hormone rather than supplying the hormone from outside. This distinction is central to how it works and how it differs from growth-hormone injections.
Our editorial team covers tesamorelin to explain its biology and its approved role, not to encourage non-medical use. Because it alters a powerful hormonal axis, it carries real risks that are easy to overlook in enthusiastic online discussion.
How it works: stimulating your own growth hormone
Rather than adding growth hormone directly, tesamorelin binds to GHRH receptors on the pituitary gland and stimulates the gland to release growth hormone in a more natural, pulsatile pattern. The released growth hormone then prompts the liver to produce insulin-like growth factor 1 (IGF-1), which mediates many of growth hormone's downstream effects.
This mechanism is often described as more physiological than injecting synthetic growth hormone, because the body's own feedback systems still have some influence over the amount released. In theory this preserves the natural rhythm of hormone secretion.
The specific effect for which tesamorelin was developed is the reduction of visceral adipose tissue, the deep abdominal fat that surrounds the organs. Growth hormone promotes the breakdown of this fat, and tesamorelin was studied specifically for that outcome.
Because it works through the body's own pituitary, tesamorelin generally will not help people whose pituitary cannot respond, and its effects depend on an intact hormonal axis.
What the clinical evidence shows
Tesamorelin's FDA approval rests on clinical trials in people with HIV who had developed excess visceral abdominal fat (lipodystrophy), a condition linked to certain HIV treatments. In these trials, tesamorelin significantly reduced visceral fat compared with placebo.
Research led by Falutz and colleagues, published in the New England Journal of Medicine (2007), showed meaningful reductions in visceral adipose tissue over 26 weeks. Later studies also suggested improvements in some blood-fat measures and, in some analyses, liver fat.
Importantly, the fat reduction tended to reverse after stopping the drug, indicating that ongoing treatment was needed to maintain the effect. This is a common pattern with hormonal interventions and is relevant to anyone imagining a short course.
The evidence base is specific to the HIV lipodystrophy population. Extrapolating these results to healthy people seeking cosmetic fat loss or anti-aging benefits is not supported by the approval data, and such uses are off-label and poorly studied.
Risks, side effects and legal context
Because tesamorelin raises growth hormone and IGF-1, its side effects overlap with those of excess growth hormone. Reported effects include joint pain, swelling of the limbs (edema), muscle aches, tingling or numbness, and reactions at the injection site.
A major concern is its effect on blood sugar. By raising growth hormone, tesamorelin can worsen insulin sensitivity and may raise blood glucose, which is particularly important for anyone with or at risk of diabetes.
Elevated IGF-1 is theoretically relevant to cancer risk because IGF-1 promotes cell growth, so the labeling advises caution and tesamorelin is contraindicated in people with active malignancy. It is also contraindicated in pregnancy and in those with certain pituitary conditions.
In the US, tesamorelin is a prescription drug; obtaining or using it without a prescription is unlawful and bypasses the medical monitoring the drug requires. For competitive athletes, growth-hormone secretagogues are prohibited by the World Anti-Doping Agency.
| Area | Potential effect | Why it matters |
|---|---|---|
| Blood sugar | Reduced insulin sensitivity | Risk for people with diabetes |
| Joints/limbs | Pain, swelling, tingling | Signs of GH excess |
| IGF-1 | Elevated levels | Caution with cancer risk |
| Hormonal axis | Altered GH secretion | Needs medical monitoring |
How tesamorelin differs from growth hormone injections
A common point of confusion is the difference between tesamorelin and injecting recombinant human growth hormone. Growth hormone injections supply the hormone directly, overriding the body's regulation. Tesamorelin instead signals the pituitary to release its own hormone.
In practice, this means tesamorelin's effect still depends on a functioning pituitary and retains more of the body's natural feedback, whereas direct growth-hormone injection does not. Both, however, ultimately raise growth hormone and IGF-1 and share many risks.
Neither approach is a shortcut free of consequences. The marketing of peptides as safer alternatives to growth hormone overstates the difference, since the downstream hormonal effects and their risks are broadly similar.
For the reader, the key takeaway is that tesamorelin is a targeted medical therapy with a narrow approved use, not a general fat-loss or longevity tool, and its risks require professional oversight.
Our Editorial Conclusions
Tesamorelin is a GHRH analog that stimulates the body's own growth-hormone release. Its sole FDA-approved use is reducing excess visceral fat in people with HIV-associated lipodystrophy, where trials showed real benefit.
Its effects reverse on stopping, it can impair blood-sugar control, and it raises IGF-1, with the usual cautions that implies. These are not trivial considerations, and the drug requires medical monitoring.
Using tesamorelin off-label for cosmetic fat loss or anti-aging is unsupported by the approval evidence, is banned in sport, and is unlawful without a prescription in the US.
For related reading, our editors suggest articles on how growth hormone works in the body, on IGF-1 and its role, and on the broader class of growth-hormone secretagogues and their risks.
References
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359–2370.
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat. J Clin Endocrinol Metab. 2010;95(9):4291–4304.
- Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA. 2014;312(4):380–389.
- US Food and Drug Administration. Egrifta (tesamorelin for injection) prescribing information. Theratechnologies; 2019.
- Clemmons DR. Metabolic actions of growth hormone in humans. Mol Cell Endocrinol. 2016;426:19–25.
- Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45–53.
